Top Markets
Coin of the day
Pharnext S.A. Pharnext S.A.

Pharnext S.A.

ALPHA
주식 순위 #42432
Based in France, Pharnext SA is a clinical-stage biopharmaceutical firm... Based in France, Pharnext SA is a clinical-stage biopharmaceutical firm dedicated to creating treatments for a range of neurodegenerative disorders, encompassing both rare (orphan) and common forms. Its pipeline features SYNGILITY, which has advanced through Phase III trials for Charcot-Marie-Tooth disease type 1A (CMT1A). Additionally, PXT864 has concluded Phase II clinical studies for Alzheimer's disease, and is also being explored for its potential in Parkinson's disease and amyotrophic lateral sclerosis (ALS). Pharnext also innovates with PLEOTHERAPY, a proprietary platform that harnesses big genetic data and artificial intelligence. In a collaborative effort, the company holds an agreement with the University Hospital Institute Mediterranee Infection to assess existing pharmaceuticals for their potential application against the COVID-19 virus. The organization was established in 2007, with its main offices located in Issy-Les-Moulineaux, France.
주가
$0.00023723
마지막 동기화: 2024-08-26
시가총액
$1.41K
변동 (1일)
111.67%
변동 (1년)
0.00%
국가
FR
거래 Pharnext S.A. (ALPHA)

카테고리

Pharnext S.A. (ALPHA)의 수익
Dec 2023 기준 수익 TTM: $-31.69M
Pharnext S.A.의 최신 재무 보고서에 따르면 회사의 현재 수익은 $-31.69M입니다. 2022년에 회사는 $-43.29M의 수익을 올렸으며 이는 2021년의 수익 $-38.48M과 감소입니다. 이 페이지에 표시된 수익은 이자 및 세금 공제 전 수익으로, 즉 EBIT입니다.
Pharnext S.A.의 수익 기록 (2013 ~ 2026)
연말 수익
연도 수익 변화
2026 (TTM) $-31.69M 1.28%
2023 $-31.29M -27.73%
2022 $-43.29M 12.50%
2021 $-38.48M 30.75%
2020 $-29.43M -0.92%
2019 $-29.70M 21.26%
2018 $-24.50M -15.52%
2017 $-29.00M 29.32%
2016 $-22.42M 87.83%
2015 $-11.94M -8.06%
2014 $-12.98M 1.29%
2013 $-12.82M 0.00%
유사 기업 또는 경쟁사의 수익
회사 수익 수익 차이 국가
$5.27B -16,747.05%
US
$1.95B -6,256.06%
NL
- -
CH
$3.01B -9,585.74%
BE
- -
KR